Pateclizumab Explained

Pateclizumab (MLTA3698A) is an immunomodulator. It binds to lymphotoxin alpha.^{[1] [2] [3] [4] [5] [6]}

This drug was developed by Genentech/Roche.

References

1. . International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 105 . WHO Drug Information . 25 . 2 . 2011 .
2. http://www.ama-assn.org/resources/doc/usan/x-pub/pateclizumab.pdf Statement On A Nonproprietary Name Adopted By The USAN Council - Pateclizumab
3. Kennedy WP, Simon JA, Offutt C, Horn P, Herman A, Townsend MJ, Tang MT, Grogan JL, Hsieh F, Davis JC . Efficacy and safety of pateclizumab (anti-lymphotoxin-α) compared to adalimumab in rheumatoid arthritis: a head-to-head phase 2 randomized controlled study (The ALTARA Study) . Arthritis Res. Ther. . 16 . 5 . 467 . October 2014 . 25359150 . 4243296 . 10.1186/s13075-014-0467-3 . free .
4. Emu B, Luca D, Offutt C, Grogan JL, Rojkovich B, Williams MB, Tang MT, Xiao J, Lee JH, Davis JC . Safety, pharmacokinetics, and biologic activity of pateclizumab, a novel monoclonal antibody targeting lymphotoxin α: results of a phase I randomized, placebo-controlled trial . Arthritis Res. Ther. . 14 . 1 . R6 . January 2012 . 22225620 . 3392792 . 10.1186/ar3554 . free .
5. Wang H, Schuetz C, Arima A, Chihaya Y, Weinbauer GF, Habermann G, Xiao J, Woods C, Grogan J, Gelzleichter T, Cain G . Assessment of placental transfer and the effect on embryo-fetal development of a humanized monoclonal antibody targeting lymphotoxin-alpha in non-human primates . Reprod. Toxicol. . 63 . 82–95 . August 2016 . 27211603 . 10.1016/j.reprotox.2016.05.014 . 41454952 .
6. Hirose T, Fukuma Y, Takeshita A, Nishida K . The role of lymphotoxin-α in rheumatoid arthritis . Inflamm. Res. . 67 . 6 . 495–501 . June 2018 . 29541795 . 10.1007/s00011-018-1139-6 . 3910200 .